Not yet recruiting NCT06939907
Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Nexpowder™.
- Who it may be relevant to
- Registry conditions: Lower Gastrointestinal Bleeding, Diverticular Bleeding. Basic parameters: from 19 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- South Korea
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract: A Prospective, Multi-Center, Single-Arm, Open-Label, Pilot Clinical Trial
Overview
Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract
Interventions
- Device Nexpowder™
Nexpowder™ hemostatic powder
Primary outcome measures
- Rebleeding rate [Time frame: 30 days post treatment]
Secondary outcome measures (2)
- Hemostasis rate [Time frame: Immediately after the procedure]
- Rebleeding rate [Time frame: 7 days post treatment]
Eligibility criteria
Inclusion criteria
- Adults aged 19 years or older at the time of screening
- Patients diagnosed with diverticular bleeding
Exclusion criteria
- Patients diagnosed with upper gastrointestinal bleeding
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
South Korea · 6 centers
- Chungbuk National University Hospital — Cheongju-si
- Chungnam National University Hospital — Daejeon
- Chosun University Hospital — Gwangju
- Sejong Chungnam National University Hospital — Sejong
- Kangdong Kyunghee University Hospital — Seoul
- Yangsan Busan National University Hospital — Yangsan
Identifiers
NCT: NCT06939907 · Nexpowder_008